Klimp A H, Hollema H, Kempinga C, van der Zee A G, de Vries E G, Daemen T
Department of Physiological Chemistry, Groningen University Institute for Drug Exploration, University of Groningen, 9713 AV Groningen, the Netherlands.
Cancer Res. 2001 Oct 1;61(19):7305-9.
This study investigates whether and to what extent cyclooxygenase type-2 (COX-2) and inducible nitric oxide-synthase (iNOS), both known to have an immunosuppressive effect, are expressed in human ovarian tumors. Because COX-2 and iNOS can be expressed by activated macrophages, the presence of tumor-associated macrophages and the expression of COX-2 and iNOS by these tumor-associated macrophages were determined. The results obtained may provide insight into the function of COX-2 and iNOS expression by tumors. The expression of COX-2 and iNOS in tumor cells and macrophages was assessed in 18 malignant, 15 borderline, and 14 benign human ovarian tumors by immunohistochemical staining of frozen tissue sections. The intra- and peritumoral macrophages were stained using an anti-CD68 monoclonal antibody. Most of the malignant tumors (15 of 18), 10 of 15 borderline, and 9 of 14 benign tumors showed COX-2 expression in the epithelial cells, a result which indicates that COX-2 expression is not exclusive to malignancy. In addition, COX-2 staining was more intense in the epithelial cells of benign and borderline tumors than in malignant tumors. Weak iNOS staining was observed in 5 of 18 malignant, 4 of 15 borderline, and 5 of 14 benign tumors. The number of tumor-associated macrophages varied widely between the different tumors. The highest number of tumor-associated macrophages (> or =20/0.125 mm(2)) was observed in malignant tumors, whereas low to moderate intra- and peritumoral macrophage infiltration (5-20/0.125 mm(2)) was observed in the borderline and benign tumors. COX-2-positive tumor-associated macrophages were found in 3 of 18 malignant tumors, 7 of 15 borderline tumors, and 1 of 14 benign tumors. The number of COX-2-positive tumor-associated macrophages ranged from 3 to 30% of the total macrophage population. Some malignant (4 of 18), borderline (5 of 15), and benign (2 of 14) tumors contained iNOS-positive macrophages. Notable was that COX-2- and iNOS-positive macrophages were predominantly located in the tumor stroma, the regions between tumor and stroma, and in the lumina of the tumor when located in the tumor tissue. These data indicate that not only malignant but also borderline and benign ovarian tumors can exhibit increased levels of COX-2 and iNOS expression. In addition, a small proportion of the tumor-associated macrophages found in malignant, borderline, and benign tumors seems to be in an activated state, judged by their iNOS and COX-2 expression. This subpopulation of tumor-associated macrophages was invariably located in the tumor stroma or in the lumina of the tumor, specifically suggesting that macrophages outside the tumor can be tumor cytotoxic.
本研究调查了已知具有免疫抑制作用的环氧化酶-2(COX-2)和诱导型一氧化氮合酶(iNOS)在人类卵巢肿瘤中是否表达以及表达程度如何。由于COX-2和iNOS可由活化的巨噬细胞表达,因此确定了肿瘤相关巨噬细胞的存在以及这些肿瘤相关巨噬细胞中COX-2和iNOS的表达。所获得的结果可能有助于深入了解肿瘤中COX-2和iNOS表达的功能。通过对冰冻组织切片进行免疫组织化学染色,评估了18例恶性、15例交界性和14例良性人类卵巢肿瘤中肿瘤细胞和巨噬细胞中COX-2和iNOS的表达。使用抗CD68单克隆抗体对肿瘤内和肿瘤周围的巨噬细胞进行染色。大多数恶性肿瘤(18例中的15例)、15例交界性肿瘤中的10例以及14例良性肿瘤中的9例在上皮细胞中显示COX-2表达,这一结果表明COX-2表达并非恶性肿瘤所特有。此外,COX-2染色在良性和交界性肿瘤的上皮细胞中比在恶性肿瘤中更强烈。在18例恶性肿瘤中的5例、15例交界性肿瘤中的4例以及14例良性肿瘤中的5例中观察到iNOS弱阳性染色。不同肿瘤之间肿瘤相关巨噬细胞的数量差异很大。在恶性肿瘤中观察到肿瘤相关巨噬细胞数量最多(≥20/0.125平方毫米),而在交界性和良性肿瘤中观察到肿瘤内和肿瘤周围巨噬细胞浸润程度低至中度(5 - 20/0.125平方毫米)。在18例恶性肿瘤中的3例、15例交界性肿瘤中的7例以及14例良性肿瘤中的1例中发现了COX-2阳性肿瘤相关巨噬细胞。COX-2阳性肿瘤相关巨噬细胞的数量占巨噬细胞总数的3%至30%。一些恶性(18例中的4例)、交界性(15例中的5例)和良性(14例中的2例)肿瘤含有iNOS阳性巨噬细胞。值得注意的是,COX-2和iNOS阳性巨噬细胞主要位于肿瘤基质、肿瘤与基质之间的区域以及位于肿瘤组织中时的肿瘤管腔中。这些数据表明,不仅恶性卵巢肿瘤,而且交界性和良性卵巢肿瘤都可表现出COX-2和iNOS表达水平升高。此外,根据其iNOS和COX-2表达判断,在恶性、交界性和良性肿瘤中发现的一小部分肿瘤相关巨噬细胞似乎处于活化状态。这一肿瘤相关巨噬细胞亚群总是位于肿瘤基质或肿瘤管腔中,特别表明肿瘤外的巨噬细胞可能具有肿瘤细胞毒性。